The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis
Dr. Dereck Mush, MD, MBA
RegCell
Epigenetic reprogramming of auto-reactive T cells into antigen-specific regulatory T cells.
What they do
RegCell develops a non-genetic epigenetic reprogramming platform that converts pathogenic auto-reactive T cells into stable, antigen-specific regulatory T cells for autoimmune disease and transplant tolerance. The company has raised $66M, including a $44M Series A led by Playground Global and non-dilutive support from Japan AMED.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Cell therapy
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Emeryville, CA
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $66M raised
Notable investors: Playground Global.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
CAR-T therapy moves beyond cancer, and autoimmune disease becomes the next proving ground
Dr. Dereck Mush, MD, MBA
CDMOs race to add capacity as cell and gene therapy demand outpaces supply
Dr. Dereck Mush, MD, MBA
A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA